01.06.2026 • Product

Chemistry.Tools: FLTMC Finalist

Chemistry.Tools is one of the finalists for the From Lab to Market Challenge.

Public Voting

Vote now on your favourite start-up in the From Lab to Market Challenge!

Vote Here
Co-Founders
Jan A. Meissner and Philipp Kuboth, Co-Founders, Chemistry.Tools.
© Chemistry.Tools

We spoke with Philipp Kuboth and Jan A. Meissner (Co-Founders) about Chemistry.Tools, one of the finalists in the From Lab to Market Challenge. 

CHEManager: What is your technology, and what makes it work?

Philipp Kuboth & Jan A. MeissnerChemistry.Tools is an AI investigation layer for chemical R&D. It combines reaction network generation with agentic AI to examine chemistry at a depth usually reserved for the highest-priority cases, turning days of expert work into hours. The agent plans investigations, runs simulations, and checks literature instead of guessing. A unique orchestration layer drives this, delivering auditable conclusions on impurities, degradation, and risk.

What problem does your technology solve, and what is the business potential?

P. Kuboth & J. A. Meissner: Chemical development loses billions to problems that could have been found earlier: missed impurities, weak process conditions, and scale-up failures that appear too late. The bottleneck is expert time. Chemistry.Tools makes deep investigation fast and routine, starting with pharma and CDMOs and expanding across chemical development.

What's the next milestone your team is working towards?

P. Kuboth & J. A. Meissner: Our AI agents can already tackle massive challenges. In a blind test, our agent took just 12 hours to autonomously find the carcinogenic side reaction behind the $650M Valsartan contamination crisis. Following this proof of concept, our next milestone is starting pilot projects with industry partners. Each pilot takes one real process and one hard chemistry question to deliver clear, actionable reports. We are actively seeking process chemists and CDMOs to launch these pilots.


Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

most read